8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Apr 23, 2026·SEC
Material company update
Mar 5, 2026·SEC
Nutex Health, Inc.(NUTX)Earnings, Financials & Key Ratios
NUTX•NASDAQ
14.4× P/E·Price updated Jun 19, 2026
AboutNutex Health, Inc. operates as a technology-enabled healthcare services company. It operates through two divisions: Hospital division and Population Health Management division. The Hospital division implements and operates health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments. This division owns and operates 21 facilities in 8 states. The Population Health Management division owns and operates provider networks, such as independent physician associations. Its management services organizations provide management, administrative, and other support services to its affiliated hospitals and physician groups. This division's cloud-based proprietary technology platform aggregates data across multiple information systems, settings, and sources to create a holistic view of each patient and provider, as well as allows to deliver care. The company is based in Houston, Texas.Show more
- Revenue$875M+82.4%
- EBITDA$296M+98.0%
- Net Income$71M+35.7%
- EPS (Diluted)10.48+7.9%
- Gross Margin50.76%+24.1%
- EBITDA Margin33.84%+8.6%
- Operating Margin31.49%+15.7%
- Net Margin8.09%-25.6%
- ROE22.64%-39.0%
NUTX Key Insights
Nutex Health, Inc. (NUTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓FCF machine: 28.1% free cash flow margin
- ✓Momentum leader: RS Rating 86 (top 14%)
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 26.1%
✗Weaknesses
- ✗Weak 3Y average ROE of 4.6%
- ✗Shares diluted 32.5% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when NUTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NUTX Price & Volume
Nutex Health, Inc. (NUTX) stock price & volume — 10-year historical chart
Loading chart...
NUTX Growth Metrics
Nutex Health, Inc. (NUTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years26.14%
3 Years58.62%
TTM40.95%
Profit CAGR
10 Years96.19%
5 Years-7.75%
3 Years-
TTM43.47%
EPS CAGR
10 Years74.25%
5 Years-15.75%
3 Years-
TTM8.36%
Return on Capital
10 Years-32.65%
5 Years1.57%
3 Years21.65%
Last Year43.23%
NUTX Recent Earnings
Nutex Health, Inc. (NUTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (50%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
Apr 30, 2026Metric
Actual
Est
EPS
$6.52+63.4%
$3.99
Rev
$216M-5.0%
$228M
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$1.61-71.0%
$5.56
Rev
$152M-41.4%
$259M
Q4 2025
Nov 19, 2025Metric
Actual
Est
EPS
$7.76+328.7%
$1.81
Rev
$268M+25.3%
$214M
Q4 2025
Oct 22, 2025Metric
Actual
Est
EPS
$2.95-105.8%
$1.43
Rev
$244M-0.0%
$244M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $6.52vs $3.99+63.4% | $216Mvs $228M-5.0% |
| Q2 2026 | Mar 5, 2026 | $1.61vs $5.56-71.0% | $152Mvs $259M-41.4% |
| Q4 2025 | Nov 19, 2025 | $7.76vs $1.81+328.7% | $268Mvs $214M+25.3% |
| Q4 2025 | Oct 22, 2025 | $2.95vs $1.43-105.8% | $244Mvs $244M-0.0% |
Based on last 12 quarters of dataView full earnings history →
NUTX Peer Comparison
Nutex Health, Inc. (NUTX) competitors in Care Delivery Networks and Value-Based Care — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ADUS | 1.76B | 94.23 | 18.09 | 23.21% | 6.89% | 9.34% | 0.19 | |
 AMSF | 588.66M | 31.32 | 12.68 | 2.63% | 14.27% | 9.68% | 0.00 | |
 UHS | 8.84B | 141.17 | 6.11 | 9.71% | 8.56% | 20.65% | 0.74 | |
 THC | 15.12B | 172.57 | 11.14 | 3.12% | 7.94% | 19.56% | 1.47 | |
 CYH | 425.61M | 3.02 | 0.80 | -1.18% | -0.41% | |||
 HCA | 83.88B | 375.17 | 13.22 | 7.08% | 8.97% | |||
 SGRY | 1.9B | 14.55 | -23.85 | 6.24% | -2.28% | -2.15% | 1.14 | |
 USPH | 964.39M | 63.32 | 44.59 | 16.33% | 1.52% | 1.36% | 0.55 |
Compare NUTX vs Peers
Nutex Health, Inc. (NUTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NUTX Income Statement
Nutex Health, Inc. (NUTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 53.65K | 91.37K | 97.06M | 274.03M | 331.53M | 219.29M | 247.65M | 479.95M | 875.26M | 879.95M |
Revenue Growth % | - | 70.32% | 106120.79% | 182.34% | 20.98% | -33.85% | 12.93% | 93.8% | 82.36% | 40.95% |
Cost of Goods Sold | 564.37K | 62.3K | 0 | 116.42M | 152.25M | 203.87M | 212.87M | 283.69M | 430.98M | 462.28M |
COGS % of Revenue | 1052% | 68.18% | - | 42.49% | 45.92% | 92.97% | 85.96% | 59.11% | 49.24% | - |
Gross Profit | -510.72K▲ 0% | 29.07K▲ 105.7% | 97.06M▲ 333716.4% | 157.61M▲ 62.4% | 179.28M▲ 13.8% | 15.42M▼ 91.4% | 34.77M▲ 125.5% | 196.26M▲ 464.4% | 444.28M▲ 126.4% | 417.67M▲ 0% |
Gross Margin % | -952% | 31.82% | 100% | 57.51% | 54.08% | 7.03% | 14.04% | 40.89% | 50.76% | 47.47% |
Gross Profit Growth % | -107874.63% | 105.69% | 333716.41% | 62.39% | 13.75% | -91.4% | 125.49% | 464.39% | 126.37% | - |
Operating Expenses | 5.69M | 1.8M | 62.35M | 4.43M | 9.02M | 422.02M | 66.55M | 65.64M | 168.66M | 145.36M |
OpEx % of Revenue | 10598.18% | 1967.03% | 64.24% | 1.62% | 2.72% | 192.44% | 26.87% | 13.68% | 19.27% | - |
Selling, General & Admin | 1.81M | 1.16M | 59.87M | 4.43M | 5.46M | 20M | 36.07M | 58.56M | 168.66M | 56M |
SG&A % of Revenue | 3380.66% | 1273.64% | 61.68% | 1.62% | 1.65% | 9.12% | 14.56% | 12.2% | 19.27% | - |
Research & Development | 25.64K | 545.22K | 0 | 0 | 285.88K | 0 | 0 | 0 | 0 | 0 |
R&D % of Revenue | 47.8% | 596.7% | - | - | 0.09% | - | - | - | - | - |
Other Operating Expenses | 3.87M | 633.57K | 2.48M | 0 | 3.27M | 402.02M | 30.48M | 7.08M | 0 | 1000K |
Operating Income | -5.69M▲ 0% | -1.83M▲ 67.8% | 34.71M▲ 1996.2% | 153.17M▲ 341.3% | 170.26M▲ 11.2% | -406.6M▼ 338.8% | -31.77M▲ 92.2% | 130.62M▲ 511.1% | 275.63M▲ 111.0% | 276.23M▲ 0% |
Operating Margin % | -10611.81% | -2003.39% | 35.76% | 55.9% | 51.36% | -185.41% | -12.83% | 27.22% | 31.49% | 31.39% |
Operating Income Growth % | -1169.04% | 67.84% | 1996.18% | 341.29% | 11.16% | -338.8% | 92.19% | 511.1% | 111.01% | - |
EBITDA | -5.16M | -1.83M | 37.19M | 159.07M | 178.02M | -393.47M | -14.18M | 149.59M | 296.15M | 297.16M |
EBITDA Margin % | -9614.51% | -2002.82% | 38.32% | 58.05% | 53.7% | -179.42% | -5.73% | 31.17% | 33.84% | 33.77% |
EBITDA Growth % | -1050.99% | 64.52% | 2132.1% | 327.75% | 11.91% | -321.02% | 96.4% | 1154.79% | 97.97% | 34.3% |
D&A (Non-Cash Add-back) | 535.02K | 522 | 2.48M | 5.9M | 7.76M | 13.13M | 17.59M | 18.97M | 20.53M | 20.93M |
EBIT | -5.64M | -840.33K | 35.62M | 152.17M | 175.69M | -407.16M | -32.17M | 129.68M | 267.01M | 189.72M |
Net Interest Income | 0 | 0 | -3.53M | -6.43M | -6.2M | -12.49M | -16.32M | -19.93M | -22.23M | -16.11M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | -367.35K | -642.07K | 3.53M | 6.43M | 6.2M | 12.49M | 16.32M | 19.93M | 22.23M | 20.79M |
Other Income/Expense | -314.55K | -983.68K | -2.62M | -7.43M | -773.88K | -13.05M | -16.72M | -20.87M | -30.84M | -26.1M |
Pretax Income | 582.06K▲ 0% | -2.81M▼ 583.5% | 32.09M▲ 1240.2% | 145.74M▲ 354.2% | 169.49M▲ 16.3% | -419.65M▼ 347.6% | -48.49M▲ 88.4% | 109.75M▲ 326.3% | 244.78M▲ 123.0% | 250.13M▲ 0% |
Pretax Margin % | 1084.99% | -3079.95% | 33.06% | 53.18% | 51.12% | -191.36% | -19.58% | 22.87% | 27.97% | 28.42% |
Income Tax | -535.02K | -161.14K | 0 | 181.34K | 965.73K | 13.09M | -5.07M | 14.48M | 64.42M | 57.81M |
Effective Tax Rate % | -91.92% | 5.73% | 0% | 0.12% | 0.57% | -3.12% | 10.45% | 13.19% | 26.32% | 23.11% |
Net Income | 582.06K▲ 0% | -2.81M▼ 583.5% | 20.92M▲ 843.5% | 105.97M▲ 406.5% | 132.59M▲ 25.1% | -424.78M▼ 420.4% | -45.79M▲ 89.2% | 52.18M▲ 214.0% | 70.79M▲ 35.7% | 96.38M▲ 0% |
Net Margin % | 1084.99% | -3079.95% | 21.56% | 38.67% | 39.99% | -193.7% | -18.49% | 10.87% | 8.09% | 10.95% |
Net Income Growth % | 107.83% | -583.5% | 843.47% | 406.47% | 25.12% | -420.36% | 89.22% | 213.96% | 35.67% | 43.47% |
Net Income (Continuing) | -6.01M | -950.13K | 32.09M | 145.56M | 168.53M | -432.74M | -43.42M | 95.27M | 180.36M | 176.36M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 22.53M | 61.56M | 76.93M | 24.46M | 17.65M | 55.55M | 93.99M | 95.76M |
EPS (Diluted) | 0.14▲ 0% | -0.39▼ 378.6% | 3.98▲ 1120.5% | 24.69▲ 520.4% | 33.55▲ 35.9% | -100.36▼ 399.1% | -10.39▲ 89.6% | 9.71▲ 193.5% | 10.48▲ 7.9% | 13.43▲ 0% |
EPS Growth % | 103.89% | -378.57% | 1120.51% | 520.35% | 35.88% | -399.14% | 89.65% | 193.46% | 7.93% | 8.36% |
EPS (Basic) | 0.14 | -0.39 | 3.98 | 24.69 | 33.55 | -100.50 | -10.39 | 10.23 | 11.13 | - |
Diluted Shares Outstanding | 4.18M | 7.18M | 4.14M | 4.29M | 3.95M | 4.23M | 4.41M | 5.1M | 6.76M | 7.18M |
Basic Shares Outstanding | 4.18M | 7.18M | 4.14M | 4.29M | 4.02M | 4.23M | 4.41M | 5.1M | 6.36M | 6.7M |
Dividend Payout Ratio | - | - | 90.34% | 55.72% | 108.86% | - | - | 12.34% | - | - |
NUTX Balance Sheet
Nutex Health, Inc. (NUTX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 55.08K | 305.42K | 45.74M | 135.51M | 154.02M | 97.97M | 90.85M | 292.48M | 538.81M | 579.65M |
Cash & Short-Term Investments | 9.45K | 119.27K | 8M | 25.51M | 36.12M | 34.26M | 22M | 43.58M | 185.57M | 207.35M |
Cash Only | 9.45K | 119.27K | 8M | 25.51M | 36.12M | 34.26M | 22M | 43.58M | 185.57M | 207.35M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 6.25K | 186.15K | 36.14M | 108.14M | 114.76M | 58.32M | 62.78M | 236.05M | 325.42M | 339.56M |
Days Sales Outstanding | 42.55 | 743.6 | 135.91 | 144.04 | 126.34 | 97.06 | 92.52 | 179.52 | 135.71 | 145.94 |
Inventory | 0 | 27.07K | 899.91K | 1.73M | 2.81M | 3.53M | 3.39M | 2.85M | 2.87M | 4.68M |
Days Inventory Outstanding | - | 158.62 | - | 5.41 | 6.75 | 6.33 | 5.81 | 3.67 | 2.43 | 2.56 |
Other Current Assets | 39.38K | -27.07K | 0 | 0 | 323.28K | 1.87M | 0 | 10M | 24.95M | 28.06M |
Total Non-Current Assets | 3.27M | 144.01K | 133.48M | 173.05M | 240.63M | 333.78M | 307.4M | 362.84M | 379.71M | 377.67M |
Property, Plant & Equipment | 3.85K | 7.61K | 131.28M | 170.81M | 238.36M | 295.15M | 269.39M | 324.69M | 343.9M | 342.18M |
Fixed Asset Turnover | 13.95x | 12.00x | 0.74x | 1.60x | 1.39x | 0.74x | 0.92x | 1.48x | 2.55x | 2.61x |
Goodwill | 0 | 0 | 3.47M | 1.14M | 1.14M | 17.01M | 17.07M | 13.92M | 13.92M | 13.92M |
Intangible Assets | 3.27M | 2.57M | 1.54M | 0 | 682.65K | 21.19M | 20.51M | 15.53M | 21.23M | 20.91M |
Long-Term Investments | 0 | 116.96K | 100K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 1.95K | 19.43K | -2.81M | 1.1M | 456.08K | 423.43K | 431.13K | 711.35K | 662K | 668K |
Total Assets | 3.33M▲ 0% | 449.43K▼ 86.5% | 179.22M▲ 39778.4% | 308.55M▲ 72.2% | 394.65M▲ 27.9% | 431.75M▲ 9.4% | 398.25M▼ 7.8% | 655.32M▲ 64.6% | 918.52M▲ 40.2% | 957.32M▲ 0% |
Asset Turnover | 0.02x | 0.20x | 0.54x | 0.89x | 0.84x | 0.51x | 0.62x | 0.73x | 0.95x | 0.96x |
Asset Growth % | 551.63% | -86.5% | 39778.36% | 72.16% | 27.9% | 9.4% | -7.76% | 64.55% | 40.16% | 284.88% |
Total Current Liabilities | 959.78K | 1.04M | 72.13M | 31.45M | 37.69M | 54.86M | 58.31M | 140.87M | 157.91M | 184.44M |
Accounts Payable | 348.35K | 567.01K | 1.75M | 8.63M | 17.65M | 23.93M | 25.28M | 13.96M | 48.97M | 46.45M |
Days Payables Outstanding | 225.3 | 3.32K | - | 27.06 | 42.32 | 42.84 | 43.35 | 17.96 | 41.47 | 34.55 |
Short-Term Debt | 386.19K | 477.06K | 13.35M | 18.65M | 10.23M | 15.17M | 14.18M | 17.95M | 14.08M | 26.27M |
Deferred Revenue (Current) | 9.1K | 9.19K | 165.56K | 38.65K | 173.92K | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 216.14K | 332.19K | 3.37M | -38.65K | 3.6M | 5.61M | 0 | 0 | 8.26M | 111.72M |
Current Ratio | 0.06x | 0.29x | 0.63x | 4.31x | 4.09x | 1.79x | 1.56x | 2.08x | 3.41x | 3.14x |
Quick Ratio | 0.06x | 0.27x | 0.62x | 4.25x | 4.01x | 1.72x | 1.50x | 2.06x | 3.39x | 3.12x |
Cash Conversion Cycle | - | -2.42K | - | 122.39 | 90.77 | 60.55 | 54.99 | 165.22 | 96.66 | 113.95 |
Total Non-Current Liabilities | 0 | 902.72K | 56.26M | 129.73M | 165.38M | 256.56M | 260.83M | 312.56M | 337.18M | 330.83M |
Long-Term Debt | 0 | 902.72K | 40.88M | 81.9M | 78.82M | 23.05M | 26.31M | 22.47M | 29.17M | 298.41M |
Capital Lease Obligations | 0 | 0 | 15.38M | 47.83M | 86.56M | 223.06M | 229.37M | 290.1M | 298.91M | 888.23M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 1.75M | 10.45M | 5.15M | 0 | 9.09M | 32.2M |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | -1.75M | 0 | 0 | 0 | 0 | 24.26M |
Total Liabilities | 959.78K | 1.95M | 128.39M | 161.19M | 203.07M | 311.42M | 319.14M | 453.43M | 495.09M | 515.26M |
Total Debt | 386.19K | 1.38M | 119.94M | 150.12M | 178.55M | 267.2M | 275.76M | 340.3M | 351.39M | 324.68M |
Net Debt | 376.74K | 1.26M | 111.94M | 124.61M | 142.43M | 232.95M | 253.75M | 296.72M | 165.82M | 117.33M |
Debt / Equity | 0.16x | - | 2.36x | 1.02x | 0.93x | 2.22x | 3.49x | 1.69x | 0.83x | 0.60x |
Debt / EBITDA | - | - | 3.23x | 0.94x | 1.00x | - | - | 2.27x | 1.19x | 1.09x |
Net Debt / EBITDA | - | - | 3.01x | 0.78x | 0.80x | - | - | 1.98x | 0.56x | 0.39x |
Interest Coverage | -15.35x | -1.31x | 10.09x | 23.66x | 28.35x | -32.60x | -1.97x | 6.51x | 12.01x | 9.13x |
Total Equity | 2.37M▲ 0% | -1.5M▼ 163.2% | 50.84M▲ 3495.0% | 147.37M▲ 189.9% | 191.58M▲ 30.0% | 120.33M▼ 37.2% | 79.11M▼ 34.3% | 201.89M▲ 155.2% | 423.44M▲ 109.7% | 537.81M▲ 0% |
Equity Growth % | 140.36% | -163.21% | 3495.03% | 189.89% | 30% | -37.19% | -34.26% | 155.22% | 109.73% | 965.17% |
Book Value per Share | 0.57 | -0.21 | 12.28 | 34.34 | 48.48 | 28.43 | 17.94 | 39.59 | 62.67 | 74.93 |
Total Shareholders' Equity | 2.37M | -1.5M | 28.31M | 85.81M | 114.65M | 95.86M | 61.45M | 146.34M | 329.45M | 442.05M |
Common Stock | 126.2K | 1.77K | 4.65K | 5.28K | 592.79K | 650.22K | 676.68K | 5.51K | 7K | 7K |
Retained Earnings | -9.65M | -5.45M | -12.57M | -18.22M | 102.32M | -363.29M | -409.07M | -356.89M | -286.19M | -239.38M |
Treasury Stock | -1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 22.53M | 61.56M | 76.93M | 24.46M | 17.65M | 55.55M | 93.99M | 95.76M |
NUTX Cash Flow Statement
Nutex Health, Inc. (NUTX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -714.62K | -480.05K | 12.12M | 86.67M | 173.43M | 50.61M | 1.26M | 23.15M | 248.13M | 272.68M |
Operating CF Margin % | -1332.08% | -525.37% | 12.49% | 31.63% | 52.31% | 23.08% | 0.51% | 4.82% | 28.35% | - |
Operating CF Growth % | -160.6% | 32.82% | 2625.71% | 614.84% | 100.1% | -70.82% | -97.52% | 1742.79% | 971.64% | 133081.19% |
Net Income | -6.01M | -950.13K | 32.09M | 145.56M | 168.53M | -432.74M | -43.42M | 95.27M | 180.36M | 96.38M |
Depreciation & Amortization | 535.02K | 522 | 2.48M | 5.96M | 7.66M | 13.13M | 17.59M | 18.97M | 20.53M | 26.49M |
Stock-Based Compensation | 924.33K | 208.03K | 0 | 0 | 0 | 189.58K | 2.84M | 16.63M | 117M | 121.54M |
Deferred Taxes | -115.22K | -123.43K | 0 | 0 | 0 | 5M | -5.71M | -13.13M | 17.08M | 16.14M |
Other Non-Cash Items | 5.52M | -160.67K | -596.94K | 1.18M | -5.51M | 400.71M | 31.62M | 9.81M | 902K | -61.55M |
Working Capital Changes | 193.65K | 310.99K | -21.85M | -66.02M | 2.75M | 64.32M | -1.66M | -104.4M | -87.74M | -57.41M |
Change in Receivables | -4K | -82.09K | -24.74M | -71.23M | -6.62M | 58.08M | -4.58M | -173.41M | -89.32M | -46.15M |
Change in Inventory | 0 | 127 | -486.27K | -825.77K | -1.09M | -719.11K | 142.7K | 540.77K | -16K | -1.56M |
Change in Payables | 119.22K | 402.25K | 1.63M | 6.23M | 6.27M | 9.69M | -2.25M | -10.72M | 37.85M | 27.92M |
Cash from Investing | 2.05K | -116.96K | -31.23M | -61.19M | -36.98M | -4.34M | -11.24M | -2.67M | -5.24M | -6.38M |
Capital Expenditures | 0 | 0 | -32.28M | -61.19M | -36.93M | -14.63M | -9.5M | -2.3M | 0 | -1.12M |
CapEx % of Revenue | - | - | 33.25% | 22.33% | 11.14% | 6.67% | 3.83% | 0.48% | 0.29% | 0.13% |
Acquisitions | -30.8K | -116.96K | 1.04M | 0 | -48.85K | 10.3M | -1.74M | -361.32K | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 32.85K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -5.24M | -5.26M |
Cash from Financing | 711.5K | 704.57K | 21.71M | -7.97M | -125.85M | -48.13M | -2.27M | 1.09M | -97.95M | -140.69M |
Debt Issued (Net) | 461K | 0 | 35.57M | 41.27M | -3.22M | -5.59M | 2.65M | -7.4M | -19.44M | -19.99M |
Equity Issued (Net) | 275K | 0 | 0 | 120K | 0 | 4.76M | 0 | 9.2M | -5M | -5M |
Dividends Paid | 0 | 0 | -18.9M | -59.05M | -144.34M | -51.23M | -5.21M | -6.44M | 0 | -42.17M |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -5M | -5M |
Other Financing | -24.5K | 756.39K | 5.05M | 9.69M | 21.71M | 3.93M | 298.03K | 5.73M | -73.51M | -73.52M |
Net Change in Cash | -1.07K▲ 0% | 109.82K▲ 10334.7% | 2.6M▲ 2271.1% | 17.51M▲ 572.5% | 10.6M▼ 39.4% | -1.86M▼ 117.6% | -12.25M▼ 557.7% | 21.58M▲ 276.1% | 144.93M▲ 571.6% | 122.92M▲ 0% |
Free Cash Flow | -714.62K▲ 0% | -480.05K▲ 32.8% | -20.15M▼ 4097.6% | 25.48M▲ 226.5% | 136.51M▲ 435.7% | 35.97M▼ 73.6% | -8.24M▼ 122.9% | 20.85M▲ 353.0% | 245.6M▲ 1077.9% | 270.22M▲ 0% |
FCF Margin % | -1332.08% | -525.37% | -20.76% | 9.3% | 41.17% | 16.4% | -3.33% | 4.34% | 28.06% | 30.71% |
FCF Growth % | -160.6% | 32.82% | -4097.63% | 226.46% | 435.67% | -73.65% | -122.91% | 353.02% | 1077.94% | 289.18% |
FCF per Share | -0.17 | -0.07 | -4.87 | 5.94 | 34.54 | 8.50 | -1.87 | 4.09 | 36.35 | 37.65 |
FCF Conversion (FCF/Net Income) | -1.23x | 0.17x | 0.58x | 0.82x | 1.31x | -0.12x | -0.03x | 0.44x | 3.51x | 2.80x |
Interest Paid | 0 | 0 | 427.4K | 3.25M | 4.1M | 4.62M | 1.64M | 3.47M | 0 | 11.86M |
Taxes Paid | 0 | 0 | 0 | 181.34K | 335.34K | 8.23M | 849.36K | 798.99K | 0 | 66.8M |
NUTX Key Ratios
Nutex Health, Inc. (NUTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 24.57% | -645.75% | 84.82% | 106.93% | 78.24% | -272.38% | -45.92% | 37.14% | 22.64% | 22.21% |
Return on Invested Capital (ROIC) | -155.5% | -109.45% | 32.03% | 52.85% | 42.15% | -88.74% | -6.95% | 23.56% | 38% | 33.27% |
Gross Margin | -952% | 31.82% | 100% | 57.51% | 54.08% | 7.03% | 14.04% | 40.89% | 50.76% | 47.47% |
Net Margin | 1084.99% | -3079.95% | 21.56% | 38.67% | 39.99% | -193.7% | -18.49% | 10.87% | 8.09% | 10.95% |
Debt / Equity | 0.16x | - | 2.36x | 1.02x | 0.93x | 2.22x | 3.49x | 1.69x | 0.83x | 0.60x |
Interest Coverage | -15.35x | -1.31x | 10.09x | 23.66x | 28.35x | -32.60x | -1.97x | 6.51x | 12.01x | 9.13x |
FCF Conversion | -1.23x | 0.17x | 0.58x | 0.82x | 1.31x | -0.12x | -0.03x | 0.44x | 3.51x | 2.80x |
Revenue Growth | - | 70.32% | 106120.79% | 182.34% | 20.98% | -33.85% | 12.93% | 93.8% | 82.36% | 40.95% |
Related:NUTX Dividend History·NUTX Revenue History·NUTX Price History·NUTX P/E History·NUTX Financial Ratios·NUTX Institutional Holders
NUTX SEC Filings & Documents
Nutex Health, Inc. (NUTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
NUTX Frequently Asked Questions
Nutex Health, Inc. (NUTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Nutex Health, Inc. (NUTX) reported $880.0M in revenue for fiscal year 2025. This represents a 69387% increase from $1.3M in 2010.
Nutex Health, Inc. (NUTX) grew revenue by 82.4% over the past year. This is strong growth.
Yes, Nutex Health, Inc. (NUTX) is profitable, generating $96.4M in net income for fiscal year 2025 (8.1% net margin).
Dividend & Returns
Nutex Health, Inc. (NUTX) has a return on equity (ROE) of 22.6%. This is excellent, indicating efficient use of shareholder capital.
Nutex Health, Inc. (NUTX) generated $270.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.